SCHEMBL3962711

SCHEMBL3962711

C[C@H](NCc1cccc(OCc2ccccn2)c1)c1cccc2ccccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR5A P47898 2/20 0.55
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
ALDH1A1 P00352 1/20 0.50
CASR P41180 4/20 0.45
GPR132 Q9UNW8 1/20 0.42
DRD2 P14416 2/20 0.42
HTR1A P08908 2/20 0.42
ABCB1 P08183 1/20 0.42
KRAS P01116 2/20 0.41
SOS1 Q07889 2/20 0.41
ADRA2C P18825 2/20 0.41
SLC6A2 P23975 2/20 0.41
HTR2C P28335 2/20 0.41
SLC6A4 P31645 2/20 0.41
OPRM1 P35372 2/20 0.41
DRD3 P35462 2/20 0.41
MLNR O43193 1/20 0.41
ABCB11 O95342 1/20 0.41
ADRB1 P08588 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8199702 1.00 HTR5A (0.55) HTR5AMEN1KMT2AALDH1A1CASR
SCHEMBL15131138 0.87 MEN1 (0.56) MEN1KMT2AALDH1A1CASRBCHE
SCHEMBL3962731 0.85 HTR5A (0.53) HTR5AMEN1KMT2AALDH1A1GPR132
SCHEMBL3344843 0.81 CASR (0.53) ALDH1A1CASRKRASSOS1
SCHEMBL2458912 0.81 CASR (0.53) ALDH1A1CASRKRASSOS1
SCHEMBL15130973 0.81 CASR (0.58) MEN1KMT2ACASRDRD2KRAS
SCHEMBL4993611 0.80 CASR (0.65) HTR5AMEN1KMT2AALDH1A1CASR
SCHEMBL8200312 0.80 CASR (0.65) HTR5AMEN1KMT2AALDH1A1CASR
SCHEMBL15131044 0.79 CASR (0.52) HTR5AMEN1KMT2AALDH1A1CASR
SCHEMBL3932126 0.78 CASR (0.48) HTR5ACASRDRD2HTR1AKRAS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2079525-A1 CALCIUM RECEPTOR MODULATING AGENTS Amgen Inc. (US) 2009-07-22 EP claimed
US-20080221101-A1 Calcium receptor modulating agents AMGEN INC. (US) 2008-09-11 US claimed
WO-2008057282-A1 CALCIUM RECEPTOR MODULATING AGENTS AMGEN INC. (US) 2008-05-15 WO claimed
US-8349831-B2 Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion AMGEN INC. (US) 2013-01-08 US disclosed
EP-2079525-A1 CALCIUM RECEPTOR MODULATING AGENTS Amgen Inc. (US) 2009-07-22 EP disclosed
US-20080221101-A1 Calcium receptor modulating agents AMGEN INC. (US) 2008-09-11 US disclosed
WO-2008057282-A1 CALCIUM RECEPTOR MODULATING AGENTS AMGEN INC. (US) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221101-A1 Calcium receptor modulating agents CASR, RYR1, RYR2 HTR5A 397/4885MEN1 2531/4885KMT2A 4786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.